OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease

Sep 21, 2022
Caroline Seymour
Article
Conference|ESMO Congress

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

Guillaume Canaud, MD, PhD

Guillaume Canaud, MD, PhD

Alpelisib (Piqray) decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum (PROS) disease who received treatment with the PI3K inhibitor under compassionate use, according to findings from the prespecified secondary end point of the retrospective EPIK-P1 study (NCT04285723) presented at the 2022 ESMO Congress.

The findings showed that lipomatosis, scoliosis, hypertrophy, inflammation, and developmental delays occurred in at least 20% of pediatric patients at the index date and were improved as early as 12 weeks. Notably, the improvement in performance status score at 24 weeks was seen in 24.2% of pediatric patients, and no patients required surgery because of disease progression during this period vs 84.6% (n = 33/39) of those who underwent at least 1 surgery (range, 1-15) between diagnosis and the pre-index period.

“In the EPIK-P1 study, a clinically meaningful proportion of pediatric patients attained response,” lead study author Guillaume Canaud, MD, PhD, and coauthors wrote in the poster. “The majority of the patients had any reduction in the sum of their target lesion volume and none of the patients had radiologically confirmed disease progression during the study period.”

Alpelisib is an oral, alpha-selective, PI3K inhibitor that received an accelerated approval from the FDA on April 6, 2022, for the treatment of adult and pediatric patients at least 2 years of age with severe manifestations of PROS who require systemic therapy. The agent has shown clinical benefit and an acceptable safety profile in prior studies performed in this population.

In primary findings from EPIK-P1, 37.5% of complete cases (n = 12/32) showed at least a 20% reduction in target lesion volume after 24 weeks.

EPIK-P1 was a retrospective, noninterventional chart review of patients at least 2 years of age with PROS experiencing severe or life-threatening conditions.

To be eligible for inclusion, patients had to receive at least 1 dose of alpelisib on or before September 23, 2019 and have relevant evaluations on or before the cut-off date of March 9, 2020.

The entire study population (n = 57) was used for all efficacy and safety analyses apart from the primary end point, which evaluated only the patients without a missing response assessment (n = 32).

The primary end point was the proportion of patients with at least a 20% reduction from the index date in the sum of measurable target lesion volume at week 24. Secondary end points included treatment effect on performance status, frequency of PROS-related surgeries, changes in signs/symptoms over time, and safety.

Of the total patient population, 39 were pediatric patients who had a median age of 10 years (range, 2-17). The overall median patient age was 14.0 years (range, 2-50). Most patients in both populations had congenital overgrowth as opposed to early childhood-onset overgrowth, mosaic distribution vs sporadic occurrence, and CLOVES subtype compared with MCAP/MCM, KTS, FIL, or other.

Pediatric patients received a median dose of alpelisib of 50.0 mg per day (range, 50.0-250.0).

Regarding safety, 79.5% (n = 31) of pediatric patients experienced at least 1 adverse effect (AE); treatment-related AEs (TRAEs) occurred in 23.1% (n = 9) of pediatric patients.

The most common any-grade AEs were diarrhea (n = 5; 12.8%), vascular malformation (n = 4; 10.3%), stomatitis (n = 3; 7.7%), aphthous ulcers (n = 3; 7.7%), inflammation (n = 3; 7.7%), hypoglycemia (n = 3; 7.7%), hyperglycemia (n = 2; 5.1%), disseminated intravascular coagulation (n = 2; 5.1%), and gait disturbance (n = 2; 5.1%). Grade 3/4 AEs included cellulitis, adrenal insufficiency, dyspnea, and wound infection (n = 1; 2.6% each).

The most frequent TRAEs were aphthous ulcer, stomatitis (n = 3; 7.7% each), and hyperglycemia (n = 2; 5.1%).

The most common serious AEs in pediatric patients were gait disturbances (n = 2; 5.1%) and vascular malformations (n = 2; 5.1%), neither of which was determined to be treatment related.

No AE led to treatment discontinuation, although 2 patients (5.1%) required dose interruptions because of AEs. No deaths occurred during the study.

“Treatment with alpelisib allowed [patients] to avoid PROS-related surgeries and resulted in improvement of performance status [and] PROS-related signs and symptoms,” the study authors wrote. “In addition to the previously reported lesion volume reduction and well tolerated safety profile, these real-world data [show] a meaningful clinical benefit with alpelisib in pediatric patients with PROS.”

The confirmatory EPIK-P2 trial (NCT04589650) is recruiting patients to further assess the efficacy, safety, and pharmacokinetics of alpelisib in pediatric and adult patients with PROS.

Reference

Canaud G, Irvine A, Ankrah N, et al. Clinical benefit of alpelisib in pediatric patients with PIK3CA-related overgrowth spectrum (PROS): an EPIK-P1 analysis. Ann Oncol. 2022;33(suppl 7):S755. doi:10.1016/annonc.2022.07.597

Related Videos
Lisa Leypoldt, MD
Marina Sharifi, MD, PhD
John Seymour, MBBS, FRACP, PhD
Natasha B. Leighl, BSc, MMSc, MD
In this third episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, share how they would best utilize genetic testing results obtained from endoscopic ultrasound–guided biopsies in pancreatic ductal adenocarcinomas.
Ticiana Leal, MD
Marcelo Vailati Negrao, MD
Shirish M. Gadgeel, MD
David Harpole, MD
Pasi A. Jänne, MD, PhD
Related Content

Sotorasib Plus Carboplatin/Pemetrexed Displays Activity, Safety in KRAS G12C+ NSCLC

September 28th 2023

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

September 27th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

FDA Approves Bosutinib for Pediatric Ph+ CP-CML

September 27th 2023

ABM-1310 Receives FDA Fast Track Designation for BRAF V600E+ Glioblastoma

September 26th 2023

Sotorasib Plus Carboplatin/Pemetrexed Displays Activity, Safety in KRAS G12C+ NSCLC

September 28th 2023

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

September 27th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

FDA Approves Bosutinib for Pediatric Ph+ CP-CML

September 27th 2023

ABM-1310 Receives FDA Fast Track Designation for BRAF V600E+ Glioblastoma

September 26th 2023

Sotorasib Plus Carboplatin/Pemetrexed Displays Activity, Safety in KRAS G12C+ NSCLC

September 28th 2023

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

September 27th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

FDA Approves Bosutinib for Pediatric Ph+ CP-CML

September 27th 2023

ABM-1310 Receives FDA Fast Track Designation for BRAF V600E+ Glioblastoma

September 26th 2023
Related Content
Advertisement
Sotorasib Plus Carboplatin/Pemetrexed Displays Activity, Safety in KRAS G12C+ NSCLC

Sotorasib Plus Carboplatin/Pemetrexed Displays Activity, Safety in KRAS G12C+ NSCLC

September 28th 2023
Article
Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021
Podcast
Gilead Discontinues Phase 3 ENHANCE-2 Trial | Image Credit: ©freshidea - stock.adobe.com

Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

September 27th 2023
Article
Gordan on Growing the Infrastructure for In-House Genomic Testing

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021
Podcast
FDA

FDA Approves Bosutinib for Pediatric Ph+ CP-CML

September 27th 2023
Article
FDA

ABM-1310 Receives FDA Fast Track Designation for BRAF V600E+ Glioblastoma

September 26th 2023
Article

Latest Conference Coverage

Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact